Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Ther Adv Med Oncol · 2019 · PMC6393951 · PMID 30833989

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the hormone receptor-positive subgroup, the benefit did not reach statistical significance: DFS was 73.4% in the control arm versus 76.4% in the capecitabine arm (HR 0.81; 95% CI 0.55–1.17), and OS 90.0% versus 93.4% (HR 0.73; 95% CI 0.38–1.40).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.